Content
57
Yahoo Finance
06/10
(Community Post)
John here's why you're not finding a Booth Number for Geron at EHA Strict Compliance and RegulationsPharmaceutical companies face intense regulatory scrutiny\. Press releases issued during major medical congresses are strictly regulated by authorities like the FDA\. These communications must focus entirely on objective scientific data and clinical trial results\. Including promotional logistics, like an exhibition booth number, can blur the line between scientific exchange and commercial marketing, potentially triggering regulatory violations\. Target Audience SeparationCompanies issue press releases for investors, journalists, and global medical professionals who are not physically attending the event\. To these audiences, a booth number is irrelevant noise\. For the select group of on\-site attendees who actually need the layout, companies rely on the congress's official directory, mobile app, and maps, which are the industry\-standard tools for navigation\. Fluid Logistics and Map ChangesExhibition floor plans at massive convention centers are highly fluid and can change leading up …...
57
Yahoo Finance
06/10
(Community Post)
From Hodl: "Then I added 20% to offset the reduced pricing factor and that left me with a total of 932 average weight patients on Rytelo for three straight months" So, Harout is fond of talking about 1450 prescriptions being "active!" 932 is only about 64% of the prescriptions being use. Something Ain't Quite Right!!!...
Votes:
1
0
57
Yahoo Finance
06/10
(Community Post)
[@u_tybhkxwqmzho](mention://user/4d80e7bd-d0c9-40a4-be22-11bb2d952674) From kram: "I don’t pump or obsess on this penny stock failure." I strongly suspect that many board members would disagree with your statement!!! Please don't worry about my interests or where I spend my time!...
Votes:
3
0
57
Yahoo Finance
06/10
(Community Post)
[@u_xmfyx8kyc6pq](mention://user/68a8c4d0-f594-491e-8746-b16f4cff3881) AI has a smaller number than I have modeled\.\.\.\.\. Based on Rytelo’s commercial pricing, dosing metrics, and gross\-to\-net financial deductions, Geron would need approximately 719 to 737 active patients taking the drug to generate $51\.8 million in net product revenue during Q1 2026\. 📇 Financial & Dosing AssumptionsQuarterly Net Product Revenue: $51\.8 millionRytelo Annual List Price \(WAC\): ~$365,000 per year \(translates to $91,250 per quarter before discounts\)Q1 Gross\-to\-Net \(GTN\) Deductions: 21% \(meaning Geron captures 79% of the list price as net revenue\)Dosing Schedule: 7\.1 mg/kg given intravenously every 4 weeks \(3 doses per quarter\) 📑 Patient Volume CalculationsDepending on whether you calculate volume using the macro annualized list price or the specific vial\-level dosing for an average patient, the estimate lands in a tight range: 1\. Annualized List Price MethodBy breaking down the standard industry list price per patient against Geron's exact Q1 deductions, we determine the net revenue …...
57
Yahoo Finance
06/10
(Community Post)
You are completely correct\. When CEO Harout Semerjian notes that Geron has roughly 1,450 prescribing/ordering accounts, that number does not equal 1,450 active, paying patient prescriptions\. Biotech companies heavily rely on "ordering accounts" as a leading metric during a drug launch, but this metric distorts the reality of active patient volume in several ways: 📑 Why "Ordering Accounts" Distort Patient VolumeCumulative vs\. Active Accounts: The 1,450 figure is a cumulative metric since launch\. It means 1,450 distinct institutions \(hospitals, community oncology clinics, or academic centers\) have ordered Rytelo at least once since it became commercially available\. It does not mean all 1,450 ordered vials this quarter\.Account\-to\-Patient Ratio: A single community oncology network account \(like US Oncology\) or a large academic medical center might order Rytelo for multiple patients, while a small rural clinic might only ever order it for one patient who has since discontinued treatment\.The "One\-and\-Done" Phenomenon: If an …...
Votes:
1
0
57
Yahoo Finance
06/10
(Community Post)
[@u_dns1q1tcdc8s](mention://user/2e56efee-38ae-4da3-b177-9f3e514400a2) You're asking a lot for a three month timeframe\. Maybe Q4 will produce that type of number but I don't think Q2 will be that high of a figure\. If we see 60 that would be huge at this point in time\....
57
Yahoo Finance
06/10
(Community Post)
we received fda approval on june 6th 2024 ,now over 2 years and we seemed to have aged well enough to sustained earnings in 50s mill,so with new mgt ,and increased overall survival i think were about to hit critical mass and im looking for 75 to 80 million earnings from all things considered including growing markets foot print \.imo\....
57
Yahoo Finance
06/10
(Community Post)
Valuation at these share prices is getting near absolute bottom. GERN currently trades at an enterprise value of $520 mil, If sales projections of 220 - 240 mil for 2026 come true, this is trading at an EV to Revenue of just over 2X, which is silly low for an emerging Biotech....
Votes:
1
0
57
Yahoo Finance
06/10
(Community Post)
From Hodl: "The 1,450 figure is a cumulative metric since launch It means 1,450 distinct institutions hospitals, community oncology clinics, or academic centers have ordered Rytelo at least once since it became commercially available" Thank you for posting this information!!! As I have posted and speculated, USING PRESCRIPTION COUNT AS A SPECIFIC METRIC IS FRAUGHT WITH UNCERTAINITY!!!!!!!!!! Fact NOT Fiction!!!...
Votes:
2
0
57
Yahoo Finance
06/10
(Community Post)
## Patient Count??? So, AI is telling us that there are ONLY about 720 patients using Rytelo? WOW, that's many less than I would have thought!!! It would appear that Geron's employee count is somewhere around 200. So, am I to believe that a few of those Geron's employees can NOT set up files on about 720 patients as to their past and current Rytelo status AND track them (get this done and then try to reconstitute former patients no longer using Rytelo)? Come on now!!! As we dig, with Hodl's help, into some of the metric details of some of Geron's performance metrics being used, we find they approach garbage status! Of course, IMO....
Votes:
3
0
57
Yahoo Finance
06/10
(Community Post)
How Geron is trying to increase Rytelo usage in the second line setting\.\.\.\.\. 1\. Refocused Commercial Targeting \("3D Surround Sound"\) Geron has restructured its sales and marketing outreach to target health care providers handling earlier\-stage patients: Account Prioritization: The company’s field team has pivoted away from low\-volume community centers that primarily handle salvage\-line cases\. They are now prioritizing high\-volume centers that treat second\-line patients who have just progressed from first\-line therapies\. Omnichannel Engagement: Geron is heavily investing in digital, non\-personal promotions and third\-party educational platforms\. This strategy creates a consistent messaging framework across medical touchpoints to help physicians identify appropriate second\-line candidates faster\. 📑 2\. Leveraging First\-Line Treatment Shifts Geron is capitalizing on changing treatment landscapes in hematology: The Luspatercept Cascade: As competitive drugs like luspatercept increasingly move into first\-line \(frontline\) usage, it creates an expanding, direct pipeline of patients who will fail frontline therapy\. Positioning as the Logical Next …...
Votes:
1
0
57
Yahoo Finance
06/10
(Community Post)
The National Comprehensive Cancer Network \(NCCN\) clinical guidelines recommend RYTELO as a preferred Category 1 and 2A treatment specifically for the second line\. The Luspatercept Tailwind: As its primary competitor, luspatercept, increasingly pushes into the first\-line frontline setting, it creates a massive, natural pipeline of failing frontline patients\. Securing the Next Step: By establishing RYTELO as the absolute mandatory second\-line standard of care, Geron ensures that as patients inevitably fail frontline treatments, they automatically flow directly onto RYTELO\....
Votes:
5
0
57
Yahoo Finance
06/10
(Community Post)
Short Interest 71,765,644 shares - source: NASDAQ Short Interest Ratio 7.09 Days to Cover Short Interest % Float 13.40 % - source: NASDAQ (short interest), Capital IQ (float) Another million or more shares short on this stock. Russian-roullete on covering going forward....
Votes:
1
0
57
Yahoo Finance
06/10
(Community Post)
Very much like Hodl's most recent post. The only hope for Geron is product use expansion. Chippy and the BOD's VERY much mislead Geron retail shareholders by suggesting that Rytelo could succeed as essentially a hail Mary drug. JNJ's punt and GS's $1 price target told investors all they needed to know about how well this product could do as a 3rd line treatment. It's a complete and total failure unless docs start prescribing it out of the box. The fact that they don't and won't combined with the POS board and top execs putting ZERO of their dollars to work in the stock pretty much says it all. This puppy is a trade when it breaches $ 1 (which I forecast happens in the next 5 trading days) and my $1.09 order was changed to a .89 order. If it hits I will add a sale order at about …...
57
Yahoo Finance
06/10
(Community Post)
At the EHA 2026 Congress, **fresh real-world data and ongoing clinical trial findings regarding the telomerase inhibitor imetelstat are being showcased by Janssen (Johnson & Johnson) and its partner, Geron**. Presentations center on imetelstat's efficacy and disease-modifying activity in lower-risk myelodysplastic syndromes (LR-MDS)...
Votes:
1
0
57
Yahoo Finance
06/10
(Community Post)
Fact Academic and industry studies indicate that less than **1% to 2%** of stocks trading under \\(\\$2\\) successfully transition into stable, mid-to-large-cap companies. The vast majority either permanently stagnate, are acquired at a steep discount, or face **involuntary delisting** and bankruptcy....
Votes:
2
0
57
Yahoo Finance
06/10
(Community Post)
Wish i had more coin to buy at this price. My dollar-cost pps is pretty low and i can wait out the next few weeks till 2nd half 2026. That's when the Rock 'n' Roll Revenues start. I am sure Harout has put some tasty carrots in view of the salespeople. Including anyone who can identify top prospects and close them. I have been in sales for several decades and know troops can overcome objections on switching from the line 2 therapy. Keep them gloves on....
Votes:
3
0
57
Yahoo Finance
06/10
(Community Post)
I guess the company doesn’t care that the share price is cratering. They’ll just do a reverse split and all will be good. Twenty for one. It will be at twenty and everything will be great. Keep up the good work executives ....
Votes:
2
0
57
Yahoo Finance
06/10
(Community Post)
Nobody ever said this stock was going to be easy. Harout had been forceful in re-aligning the ship in short time. A year is not much time to turn it around for any new CEO. He replaced dead weight and inefficient salespeople with experienced big pharma and biotech aces. These people can use existing relationships with health networks, doctors, and researchers. These folks will trust and take a leap from status quo to help outcomes in line 2. The data does not lie with imetelstat....
Votes:
3
0
57
Yahoo Finance
06/10
(Community Post)
RS?? That's the best joke of the last 15 yrs....you really think that these big time holders would be holding on (as some of us are), if they even had an inkling of a possible RS?? The would have left here faster than the Road Runner!!!! BUT....they are still here!!!! As I.........
Votes:
2
0
57
Yahoo Finance
06/10
(Community Post)
in 30 years this stock has never held support and always breaks down like a sinkhole thru ALL SUPPORT LEVELS so let me give you a tip you can win with ,its going to \.85 cents \.because it is the most untrusted stock i have ever seen ,just bizarre\....
Votes:
1
0
57
Yahoo Finance
06/10
(Community Post)
all thats left for management to try is start buying back stock and cancel shelf financing permanently\.and do it tomorrow thru a press release and the reason they are confident profit will support a buy back\. harout needs to get agressive\....
57
Yahoo Finance
06/10
(Community Post)
Who would have thought that Gercon receives FDA approval for ImetelCrappy and year later the stock price is $1.10 ??? 😂 ...
Votes:
3
0
57
Yahoo Finance
06/10
(Community Post)
when covid was announced geron had approx 200 million shares in 2018 then after covid 2021 2022 geron had 400 million outstanding and currently geron has 641 million shares so we have already lost 90 /95 % of whatever percieved value we invested in, i dont know about you but me i am yelling "UNCLE" give me 4 and let me out\....
Votes:
2
0
57
Yahoo Finance
06/10
(Community Post)
[@short22052](mention://user/78a147e2-5d63-4d00-9898-1560e9fd3737)i don't think harout is hiding anything , what we are paying for is the sins of previous management, a sunami of shares after the j&j /janssen earthquake that happened in 2018 , we sold our soul to stay alive and we clearly should have sold this company before the vulchersw di looted us into worthless obliven ....
Votes:
1
0
57
Yahoo Finance
06/10
(Community Post)
eu approval and no launch???once data readout for mf than sp will move dramatically....the mayo pilot study 2013 mf was the needle mover not mds. ....herons drug is superior on mf as it takes on the disease not just the symptoms...
Votes:
4
0
57
Yahoo Finance
06/10
(Community Post)
At the European Hematology Association (EHA 2026) Congress in Stockholm, Geron Corporation and [**Janssen**](https://firstwordpharma.com/story/4473666)**highlighted clinical and real-world evidence for imetelstat ([RYTELO](https://www.globenewswire.com/news-release/2026/05/12/3293010/35501/en/first-real-world-evidence-study-of-rytelo-imetelstat-in-lower-risk-myelodysplastic-syndromes-lr-mds-to-be-presented-at-eha-2026.html))**...
Votes:
2
0
57
Yahoo Finance
06/11
(Community Post)
[@jim1031](mention://user/3f920880-4925-4443-80a3-27dfab901607) Why hasn't Harout made Europe a priority. The approval in Europe won't help the stock unless a partner is obtained to market the drug. He has had plenty of time to address the issue. Very disappointed....
57
Yahoo Finance
06/11
(Community Post)
Is it coincidence that this stock is crashing right during and after the two biggest hematology shows? These shows are attendees by thousands of hematologists and also by the institutional investors who send groups of people to interview these hematologists to get their view of particular drugs it is entirely likely that they heard a lot of skepticism, doubt and resistance to Imetelstat and have been trimming their holdings. These institutions know more than you do because they have the resources to do the research that you or I can’t...
Votes:
2
0
57
Yahoo Finance
06/11
(Community Post)
i had a dream last night ,and it was of the curse of the bambino that s when the red sox traded babe ruth to the yankees,and the falling knife geron curse is they actually fired stephen gryaznov imetelstat inventer ,and then decided to go from 10 million ipo shares in the ninetys to todays 641 million they sold off our heart and soul\.leaving us groveling for "FOUR"\....
57
Yahoo Finance
06/11
(Community Post)
GSK is buying Nuvalent for $10.6 billion. Lung cancer company with two drugs expecting FDA approval later this year, and one in earlier stage trials. No current revenue. GSK building up their oncology business through acquisitions. Add GSK to the list of potential buyers. jmho...
Votes:
3
0
57
Yahoo Finance
06/11
(Community Post)
Only 2 things save this stock - either there is a big uptick in prescriptions or they are bought. They have has 6 quarters to show they can drive adoption and boost prescriptions and we have a $50mil a quarter to show for it....
Votes:
1
0
57
Yahoo Finance
06/11
(Community Post)
Anyone else load the truck at these insane levels? Congrats if you did. The hedge funds just wiped out a boatload of retail that invested in this since early 2025 or later. Tutes and hedge funds control most of this now. The insiders have a pittance like 0.32% of float still. Waiting for the inside buying to occur. Greed will take over the remaining Geron staff to buy this low level soon. Most have to wait for several years to cash in their options. ...
Votes:
2
0
57
Yahoo Finance
06/11
(Community Post)
At the European Hematology Association (EHA 2026) Congress, [**Johnson & Johnson**](https://www.jnj.com/media-center/press-releases/johnson-johnson-showcases-hematology-leadership-with-30-presentations-at-the-2026-european-hematology-association-eha-congress) (which holds worldwide commercialization and development rights via [**Janssen Biotech, Inc.**](https://firstwordpharma.com/story/4473666) from Geron Corporation) highlighted **real-world evidence for imetelstat, known by the brand name RYTELO [First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-...](https://www.globenewswire.com/news-release/2026/05/12/3293010/35501/en/first-real-world-evidence-study-of-rytelo-imetelstat-in-lower-risk-myelodysplastic-syndromes-lr-mds-to-be-presented-at-eha-2026.html).** \[[1](https://firstwordpharma.com/story/7422776)\]...
Votes:
1
0
57
Yahoo Finance
06/11
(Community Post)
Short Interest **71,765,644 Shares** - source: NASDAQ Short Interest Ratio 6.57 Days to Cover Short Interest % Float 13.40 % - source: NASDAQ (Short Interest), Capital IQ (float) **That's alot of cheese to cover.** ...
Votes:
3
0
57
Yahoo Finance
06/11
(Community Post)
The Geron sales team are closing more U.S. and EU accounts in qtr 2 and rest of year. The guideance is net profit for 2026. Phase 3 prelim study result will be exciting and lift the stock above $2 and next thing you know; pps at $4. As the pps rises, aquisitions could be on the horizon. Maia come to mind?...
Votes:
1
0
57
Yahoo Finance
06/11
(Community Post)
[@jim1031](mention://user/3f920880-4925-4443-80a3-27dfab901607) Jim, Geron does not get any results from IMpactMF unless the IDMC halts the trial at the interim\. Otherwise we won't know any more than what we now know and will have to wait until the final readout in the second half of 2028\....
57
Yahoo Finance
06/11
(Community Post)
Nice volume today. Washed out the weak hands once again. The climb to $2.00 begins again. This time revenue growth will accelerate due to EU sales set at good terms by Harout's team. The Phase 3 study, insider buying, and more hedge funds piling in should do the trick in 2026....
Votes:
3
0
57
Yahoo Finance
06/11
(Community Post)
[@jim1031](mention://user/3f920880-4925-4443-80a3-27dfab901607) jim: Why do you guys continually IGNORE the effect of the Most Favored Nation Order??? Harout's team can NOT give the EU good terms (lowered price) without effecting Rytelo's U.S. price! Fact NOT Fiction!!!...
Votes:
3
0
57
Yahoo Finance
06/11
(Community Post)
2nd line market share. Geron's year to take it! Once the EU starts ramping up sales, the US patients will demand it even more. Shorts, you hear this? Walk the fire baby! ...
Votes:
4
0
57
Yahoo Finance
06/11
(Community Post)
The US stock market is surging today primarily because President Donald Trump unexpectedly cancelled planned evening military strikes against Iran, triggering a massive sigh of relief across Wall Street\. This sudden geopolitical de\-escalation caused crude oil prices to tumble and prompted investors to aggressively buy the dip in heavily beaten\-down semiconductor and artificial intelligence \(AI\) stocks...
Votes:
3
0
57
Yahoo Finance
06/11
(Community Post)
Marango, this may unrest your case\. Yes, the IDMC sees unblinded data long before the official interim readout is triggered\. However, how they look at it and what they can do with it changes dramatically before versus after that trigger\. The process is divided into two distinct operating modes: 1\. Before the Trigger: Safety\-Only ReviewsWhile the death count is slowly climbing toward the interim threshold, the IDMC meets regularly \(usually every 6 months\) for Routine Safety Reviews\.What they see: The unblinded, granular safety data\. They see exactly which patients are experiencing severe side effects, hematologic toxicities, or early treatment\-related deaths\.What they do not do: They do not run formal statistical "efficacy calculations" or check if imetelstat is winning\. They avoid looking closely at comparative survival efficacy to prevent taking a "statistical penalty" \(which degrades the trial's mathematical power\)\.Their only goal: To ensure the drug is not actively harming patients\. They …...
Votes:
1
0
57
Yahoo Finance
06/11
(Community Post)
From Hodl: "Marango, this may unrest your case" NO, Hodl, your post did NOT unrest my case!!! I'll stick with the following!!! "Hodl: If the IDMC does NOT halt the trial at the Interim, I'm going to be very surprised and disappointed! Why? It will INDICATE to me that the Phase 2 data were "distorted" and something was "distorted" about the several delays for the MF Interim!!! I'll use the term "distorted" because I'm not sure what term would be proper at this point in time!" Now we wait and see what really happens! Of course, IMO...
Votes:
1
0
57
Yahoo Finance
06/11
(Community Post)
Triple-bagger in 2026. Taking it day-by-day. The catalysts will start happening soon. Revenues will accelerate like no other. ...
Votes:
3
0
57
Yahoo Finance
06/11
(Community Post)
GERN says EU sales are up, USA sales are up, over $400 million in cash, MF patients are living longer and longer and gern's drug is working great in combination with other drugs and the analysts are calling gern a 2026 $4 stock...
Votes:
5
0
57
Yahoo Finance
06/11
(Community Post)
[@u_xmfyx8kyc6pq](mention://user/68a8c4d0-f594-491e-8746-b16f4cff3881) LOL, nice to see you added the words " At the Interim " Yes then I can agree that I too would be disappointed if it's not halted for efficacy\. All indications lean towards a halt\. Science is replicable therefore phase 3 will be at least as good as phase 2 but should even beat it due to patient selection criteria from where our subset of Phase 2 patients did extremely well\. Dr Scarlett and the team designed this trial to be halted at the interim readout\. Updated\.\. Marango, my bad, you did qualify your post with at the interim, I missed it\....
Votes:
3
0
57
Yahoo Finance
06/11
(Community Post)
## What's going on today? Mechanically Why the "Tutes" are Stepping InExploiting the Oversold Reversal: Prior to today, GERN had suffered heavy selling pressure, plunging roughly 26\.6% over the trailing four weeks\. This drove GERN's Relative Strength Index \(RSI\) deep into oversold territory \(below 30\)\. Algorithmic institutional buyers use oversold scanners to trigger massive buy programs when a stock's underlying fundamentals remain strong but the price becomes temporarily disconnected\. Strong Fundamental Baseline: Institutions are looking past the short\-term chart weakness to GERN's structural turnaround\. The company recently posted $51\.8 million in net product revenue for RYTELO, and Wall Street analysts have actively been raising EPS estimates by up to 57\.9%\. Existing Institutional Dominance: Institutions already own approximately 61% of Geron's total float\. When a low\-volume slump pushes an already heavily institutionalized stock to multi\-month lows, those same large players routinely scale into larger positions \(averaging down\) rather than allowing their …...
Votes:
1
0
57
Yahoo Finance
06/11
(Community Post)
While I'm linking many of my comments to the MF Interim, I'm afraid that it's release may slide into 2027!!! Why? The patients are living longer, which is a very good thing, but the 112 metric may become elusive. I'm 50-50 on whether the Q2 will show anything "remarkable" or not! Remember that the $52Million in Revenue and additional 150 Prescriptions reported in the Q1 did little to help the PPS!!! The Q3 is too far out to assess/ speculate! So, here we are Wait'n and Watch'n!!! Of course, IMO....
Votes:
1
0
57
Yahoo Finance
06/11
(Community Post)
[@u_xmfyx8kyc6pq](mention://user/68a8c4d0-f594-491e-8746-b16f4cff3881) The longer it takes to trigger the readout, the better the results will be\. I believe we've reached the point where the system is going to start to naturally flow Luspatercept first line failures straight onto Rytelo in the second line\. This will drive our revenue organically leading to increased quarterly growth, quarter after quarter and this is what the market wants and needs to see to obtain fair value\....
Votes:
2
0
57
Yahoo Finance
06/11
(Community Post)
Rocky and ER are correct. The shorts cannot keep this down much longer. Revenues very likely to rise with EU sales in the equation now. Harout and team can get the best pricing and get past sticky EU regulations and roadblocks. The quarter is almost over and the commercial and legal team are going to negotiate good long-term deals....
Votes:
3
0
57
Yahoo Finance
06/11
(Community Post)
## This Might Be Where Rytelo is Presented: **J&J / Janssen Portfolio:** Imetelstat sits within a broad portfolio of over 30 hematology abstracts showcased by Johnson & Johnson at the Stockholm meeting, which also features updates on treatments like Talvey and Carvykti...
57
Yahoo Finance
06/11
(Community Post)
- First real‑world RYTELO study in lower‑risk MDS heads to EHA 2026, tracking outcomes in heavily transfusion‑dependent patients, even after luspatercept failure. - Early real‑world data show a 37.5% red blood cell transfusion independence rate with safety in line with prior RYTELO trials and stronger signals when used earlier. - Geron says real‑world RYTELO results broadly match Phase 3 IMerge in tough lower‑risk MDS populations, backing the commercial story....
Votes:
2
0
57
Yahoo Finance
06/11
(Community Post)
Geron is firing on all cylinders in verifying data in real-world clinical setting outside the studies. Luspatercept (Reblozyl) is getting close to losing a large chunk of Line 2 business. Geron is showing the street it is Already looking at other blood cancers in studies while increasing sales of Rytelo in Line 2. Harout is a master at hiring key people with big pharma sales experience and they already have segwayed into EU sales. They can pre-sell new pipeline drugs in development which Wall St sees additional sales possibly in late 2027 and for sure 2028. By then, the Geron team will be masters at getting fast-track status on the new blood drugs....
Votes:
6
0
57
Yahoo Finance
06/11
(Community Post)
## Rytelo clinically is a good blood cancer medicine. It is approved in the USA and Europe. In combination, it may become a great medicine (disease modification, kills cancer stem cells). Big Pharma needs a pipeline. Geron needs Big Pharma's protection from market manipulations....
Votes:
1
0
57
Yahoo Finance
06/11
(Community Post)
India Rytelo Distributor [https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=https://indianpharmanetwork.co.in/medicines/product/rytelo-imetelstat-price-india/&ved=2ahUKEwiYz6ra0YCVAxVWLkQIHSJkFMU4MhAWegQIFhAB&usg=AOvVaw1gyNvCM56Bx2vCCx_uNPha](https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=https://indianpharmanetwork.co.in/medicines/product/rytelo-imetelstat-price-india/&ved=2ahUKEwiYz6ra0YCVAxVWLkQIHSJkFMU4MhAWegQIFhAB&usg=AOvVaw1gyNvCM56Bx2vCCx_uNPha)...
Votes:
2
0
(Community Post)